Genentech’s Faricimab Data Show Promise Of New Treatment For Two Common Causes Of Blindness

(RTTNews) – Genentech, a member of the Roche Group (RHHBY), said that four phase III studies data on bispecific antibody, faricimab, showed the promise of a new treatment for two common causes of blindness, diabetic macular edema or DME and neovascular age-related macular degenerRead MoreMarketsMarkets Feed

¡Haz clic para votar esta entrada!
(Votos: 0 Promedio: 0)

Deja un comentario